As AbbVie Ireland’s new general manager, Dana Kendall will oversee the company’s commercial business in the country.

This highly anticipated drug is expected to become a key treatment for prurigo nodularis and atopic dermatitis. Galderma’s midterm targets for the period 2023 to 2027 are for low- to mid-teens ...

Antibody-drug conjugates (ADCs) represent a promising cancer treatment modality designed to deliver highly potent cytotoxic ...